Clinical Trials Directory

Trials / Completed

CompletedNCT03275857

Cisplatin in Castration Resistant Prostate Cancer

A Pilot Study of Cisplatin in Castration Resistant Prostate Cancer That is Becoming Refractory to Enzalutamide

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
12 (actual)
Sponsor
University of Rochester · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.

Conditions

Interventions

TypeNameDescription
DRUGCisplatinWeekly IV

Timeline

Start date
2018-09-21
Primary completion
2023-07-31
Completion
2023-07-31
First posted
2017-09-08
Last updated
2024-06-10

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03275857. Inclusion in this directory is not an endorsement.

Cisplatin in Castration Resistant Prostate Cancer (NCT03275857) · Clinical Trials Directory